Source link : https://newshealth.biz/health-news/avapritinibs-effect-durable-in-indolent-systemic-mastocytosis/
Long-term data from the PIONEER trial, presented at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting, support the durability of response with the KIT inhibitor avapritinib (Ayvakit) for indolent systemic mastocytosis. In this exclusive MedPage Today video, Tsewang Tashi, MD, of the University of Utah Huntsman Cancer Institute in Salt Lake City, […]
The post Avapritinib’s Effect Durable in Indolent Systemic Mastocytosis first appeared on News Health.
—-
Author : News Health
Publish date : 2026-03-24 17:21:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8